Mounjaro 2.5 mg (Tirzepatide) Pen – 4 Pack

Mounjaro 2.5 mg is the starting dose of the prescription, once-weekly injectable medication containing the active ingredient Tirzepatide. Manufactured by Lilly, Mounjaro is a breakthrough first-in-class treatment approved for adults with type 2 diabetes to improve blood sugar control. It is also widely known for its significant weight loss effects.

Product Overview: Mounjaro 2.5 mg (Tirzepatide)

Mounjaro (Tirzepatide) is a unique medication. It is the first and only dual-action GIP and GLP-1 receptor agonist. This dual mechanism targets two key hormones that regulate blood sugar and appetite.

The 2.5 mg dose is the initial “titration” dose. It is not considered a therapeutic dose for blood sugar control. Its purpose is to slowly introduce the medication to your body, helping to minimize potential gastrointestinal side effects (like nausea) before moving to the higher maintenance doses.

This package contains 4 single-dose, pre-filled pens, providing a 4-week supply.

How Does Mounjaro (Tirzepatide) Work?

The active ingredient, Tirzepatide, works by activating two separate hormone receptors:

1. GLP-1 (Glucagon-like peptide-1): This helps stimulate insulin release, reduce sugar production from the liver, and slow down digestion, making you feel full.
2. GIP (Glucose-dependent insulinotropic polypeptide): This also enhances insulin release and is believed to play a role in fat metabolism and appetite regulation.

By targeting both pathways, Mounjaro provides powerful control over blood sugar (A1C) and appetite, leading to significant weight loss in many patients.

Key Product Details

Dosage and Administration

Mounjaro is a once-weekly subcutaneous injection (an injection under the skin) that you can administer yourself.

• Starting Dose: The 2.5 mg dose is taken once a week for the first 4 weeks of therapy.
• Titration: After 4 weeks on the 2.5 mg dose, your healthcare provider will typically increase your dose to 5 mg once weekly.
• Note: The 2.5 mg dose is for initiation only; it is not a maintenance dose.

Important: This is a prescription-only medication. You must follow the exact titration and dosing schedule prescribed by your healthcare provider.

Frequently Asked Questions (FAQ) about Mounjaro 2.5 mg

Is 2.5 mg a “weight loss” dose for Mounjaro?

The 2.5 mg dose is the starting dose to help your body acclimate to the medication. While some people may begin to lose weight on this dose, the higher maintenance doses (5 mg, 10 mg, 15 mg) are associated with the significant weight loss seen in clinical trials.

What is the difference between Mounjaro (Tirzepatide) and Ozempic (Semaglutide)?

Ozempic (Semaglutide) is a GLP-1 receptor agonist. Mounjaro (Tirzepatide) is a dual-action GIP and GLP-1 receptor agonist. This dual mechanism is unique to Mounjaro and is why it has shown different results in clinical studies.

How must Mounjaro pens be stored?

• Unopened Pens: Must be stored in a refrigerator (between 2°C and 8°C or 36°F and 46°F).
• In-Use Pens: If needed, a single pen can be stored at room temperature (below 30°C or 86°F) for up to 21 days.
• Do not freeze Mounjaro.

What are the most common side effects of Mounjaro?

The most common side effects are gastrointestinal. These include nausea, diarrhea, decreased appetite, vomiting, and constipation. These are most common when starting the 2.5 mg dose and usually decrease as your body adjusts.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

• Tirzepatide (Mounjaro) has been shown to cause thyroid C-cell tumors in animal studies. It is not known if Mounjaro causes these tumors in humans.
• Do not use Mounjaro if you or any of your family members have ever had Medullary Thyroid Carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Before taking Mounjaro, tell your doctor about your full medical history, especially if you have:

• A history of pancreatitis (inflammation of the pancreas).
• Kidney problems or diabetic retinopathy.
• Severe gastrointestinal (stomach) problems.
• Are pregnant, planning to become pregnant, or breastfeeding.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Mounjaro (Tirzepatide) is a prescription medication with serious risks. Always consult with your healthcare provider to see if Mounjaro is right for you.